tradingkey.logo
tradingkey.logo
検索

Eton Pharmaceuticals Inc

ETON
ウォッチリストに追加
37.500USD
+0.870+2.38%
終値 07/02, 13:00ET15分遅れの株価
1.03B時価総額
損失額直近12ヶ月PER

詳細情報 Eton Pharmaceuticals Inc 企業名

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.

Eton Pharmaceuticals Incの企業情報

企業コードETON
会社名Eton Pharmaceuticals Inc
上場日Nov 09, 2018
最高経営責任者「CEO」Brynjelsen (Sean E)
従業員数31
証券種類Ordinary Share
決算期末Nov 09
本社所在地21925 W Field Pkwy Ste 235
都市DEER PARK
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号60010-7278
電話番号18477877361
ウェブサイトhttps://etonpharma.com/
企業コードETON
上場日Nov 09, 2018
最高経営責任者「CEO」Brynjelsen (Sean E)

Eton Pharmaceuticals Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Sean E. Brynjelsen
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
828.68K
-14.48%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
169.56K
+32.33%
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
93.42K
--
Mr. Paul V. Maier
Mr. Paul V. Maier
Independent Director
Independent Director
84.75K
--
Mr. James R. Gruber
Mr. James R. Gruber
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
15.96K
-36.06%
Ms. Ipek Erdogan-Trinkaus
Ms. Ipek Erdogan-Trinkaus
Chief Commercial Officer
Chief Commercial Officer
289.00
--
Ms. Jennifer (Jenn) Adams
Ms. Jennifer (Jenn) Adams
Independent Director
Independent Director
--
--
Mr. David C. Krempa
Mr. David C. Krempa
Chief Business Officer
Chief Business Officer
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Sean E. Brynjelsen
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
828.68K
-14.48%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
169.56K
+32.33%
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
93.42K
--
Mr. Paul V. Maier
Mr. Paul V. Maier
Independent Director
Independent Director
84.75K
--
Mr. James R. Gruber
Mr. James R. Gruber
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
15.96K
-36.06%
Ms. Ipek Erdogan-Trinkaus
Ms. Ipek Erdogan-Trinkaus
Chief Commercial Officer
Chief Commercial Officer
289.00
--

よくある質問

Eton Pharmaceuticals Incの上位5名の株主は誰ですか?

Eton Pharmaceuticals Incの上位5名の株主は以下のとおりです。Mr. Sean E. Brynjelsen

Eton Pharmaceuticals Inc(ETON)の株式を保有している機関の数はいくつですか?

2026Q1時点で、Eton Pharmaceuticals Incの株式を保有している機関は235社あり、保有株式の総市場価値は約15.99Mで、全体の58.43%を占めています。2025Q4と比較して、機関の持ち株は-3678435.00増加しています。